Innovation in nanomedicine: nanocarriers for central nervous system disorders management

Rising prevalence of Central Nervous System (CNS) illnesses poses an issue of concern for global health, requiring new and innovative treatment approaches. Current treatments for neurological disorders, such as Alzheimer’s and Parkinson’s diseases, exhibit limited effectiveness and fail to halt disease progression. This study highlights the use of beta-cyclodextrin-mediated nanocarriers as a potential option to enhance dissemination of drug compounds across blood-brain barrier (BBB) and also examines use of cyclodextrin-based nanoparticles in encapsulating and administering medicinal substances to CNS. Beta-cyclodextrin nanocarriers have potential to greatly transform treatment of CNS illnesses, providing opportunity for individuals with these severe conditions. Beta-cyclodextrin nanocarriers enhance both solubility and stability of medications, while also enabling their precise transport to brain. These nanoparticles are able to form inclusion complexes, enhance water solubility and facilitate targeted drug administration. Enhanced efficiency of these nanocarriers in crossing blood brain barrier (BBB), results in a substantial increase in the amount of drugs available in brain. This novel method offers a practical and efficient way to distribute drugs, which may help close existing gap in research. Consequently, it has capacity to result in notable improvements in area of medicine that treats diseases of central nervous system.